CARR PowerFuge Pilot Separation System
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FOOD AND DRUG ADMINISTRATION
Contract Value
Not provided
Codes & Classification
Solicitation Number
75F40126Q00172
NAICS
334516 - Analytical Laboratory Instrument Manufacturing
Classification Code
6640
Additional Details
Documents2
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a Combined Synopsis/Solicitation for the procurement of a CARR PowerFuge Pilot Separation System. This notice, identified by procurement number 75F40126Q00172, represents a revision from the original Notice of Intent to Sole Source, reflecting the agency’s decision to solicit quotations from authorized distributors after receiving information about additional capable sources.
The primary objective of this procurement is to acquire a specialized analytical laboratory instrument, specifically a pilot separation system, to support the FDA’s operational and research needs. The CARR PowerFuge system is expected to deliver advanced separation capabilities, likely for laboratory analysis and sample processing, aligning with the agency’s mission to ensure public health and safety through scientific excellence.
The scope of this solicitation encompasses the supply of the required equipment, with all quotations to be submitted in accordance with the detailed requirements and instructions provided in the solicitation documents. The procurement is classified under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing), with a corresponding Product Service Code of 6640, indicating a focus on laboratory equipment and supplies.
This opportunity is set aside for Small Business Administration (SBA) eligible entities, ensuring that small businesses have the opportunity to participate in the procurement process. The place of performance is within the United States, and the FDA is seeking responses from authorized distributors capable of providing the specified system.
Interested contractors should note that the FDA is the contracting entity, and all inquiries or submissions should be directed to the primary contact, Jennifer Mun, at [email protected]. The notice remains active, with a posting date of September 9, 2026, and a response deadline of September 14, 2026. Additional information, including attachments relevant to the solicitation, can be accessed via the official SAM.gov opportunity page at https://sam.gov/opp/940ce7dc64614f61971a9c6ebf223d2f/view.
Contractors evaluating this opportunity should ensure their capabilities align with the requirements for analytical laboratory instrument manufacturing and distribution, and that they meet SBA set-aside eligibility. The FDA’s procurement process will remain consistent throughout the contract lifecycle, focusing on compliance with federal acquisition regulations, delivery of high-quality laboratory equipment, and adherence to the specified performance location and timelines.